Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)


Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully commercialize DEGEVMA (denosumab-adet) a Biosimilar to Xgeva® (denosumab) for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone, and for the treatment of hypercalcemia of malignancy, and PONLIMSI (denosumab-adet); our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned “Risk Factors” and “Forward-looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.



Source link

  • Related Posts

    Sangoma Technologies Corporation Enters into Definitive Agreement to be Acquired by BRC Group Holdings, Inc.

    Particularly, statements regarding the Transaction, including the proposed timing and various steps contemplated in respect of the Arrangement, the ability to complete the Arrangement and the other transactions contemplated by…

    Continue reading
    Slate Delivers Strong Return for Investors in North American Essential Real Estate Strategy

    “This outcome supports what we have long believed: that grocery-anchored real estate is a high-quality, in-demand asset class, and active in-house management can create measurable value for investors. We are…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Experts worry about Nvidia’s AI chip sales in China and influence over Trump

    Experts worry about Nvidia’s AI chip sales in China and influence over Trump

    Giants to trade for Vikings’ J.J. McCarthy

    Giants to trade for Vikings’ J.J. McCarthy

    Activision Keeps Saying All The Right Things About Modern Warfare 4

    Activision Keeps Saying All The Right Things About Modern Warfare 4

    99 Healthy Lunch Recipes For Going Back To Work Or School

    99 Healthy Lunch Recipes For Going Back To Work Or School

    Shark’s NeverChange Air Purifier Is Nearly Half Off Right Now

    Shark’s NeverChange Air Purifier Is Nearly Half Off Right Now

    Tuesday, September 29, 2026 | Prime Minister of Canada

    Tuesday, September 29, 2026 | Prime Minister of Canada